These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 15614149)

  • 1. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients.
    Freeman RB; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Heaton N;
    Transplantation; 2004 Dec; 78(12):1765-73. PubMed ID: 15614149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.
    Paya C; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Pescovitz MD;
    Am J Transplant; 2004 Apr; 4(4):611-20. PubMed ID: 15023154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients.
    Cervera C; Pineda M; Linares L; Marcos MA; Esteva C; Antón A; Cofán F; Ricart MJ; Navasa M; Pérez-Villa F; Pumarola T; Moreno A
    Transplant Proc; 2007 Sep; 39(7):2228-30. PubMed ID: 17889146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapsing cytomegalovirus infection in solid organ transplant recipients.
    Shanahan A; Malani PN; Kaul DR
    Transpl Infect Dis; 2009 Dec; 11(6):513-8. PubMed ID: 19735385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.
    Len O; Gavaldà J; Aguado JM; Borrell N; Cervera C; Cisneros JM; Cuervas-Mons V; Gurguí M; Martin-Dávila P; Montejo M; Muñoz P; Bou G; Carratalà J; Torre-Cisneros J; Pahissa A;
    Clin Infect Dis; 2008 Jan; 46(1):20-7. PubMed ID: 18171208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Cytomegalovirus Infection on Survival of Older Kidney Transplant Patients (D+/R+): Impact of Valganciclovir Prophylaxis Versus Preemptive Therapy.
    Luna E; Caravaca F; Ferreira F; Fernandez N; Martín P; Vargas ML; Saenz de Santamaría J; Garcia Pino G; Azevedo L; Muñoz Sanz A
    Transplant Proc; 2016 Nov; 48(9):2931-2937. PubMed ID: 27932110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
    Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP;
    Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy.
    Kalil AC; Freifeld AG; Lyden ER; Stoner JA
    PLoS One; 2009; 4(5):e5512. PubMed ID: 19436751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
    Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease.
    Belga S; Hernandez C; Kabbani D; Cervera C
    Transpl Infect Dis; 2024 Apr; 26(2):e14227. PubMed ID: 38180285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
    Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study.
    Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L
    Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin.
    Gutiérrez CA; Chaparro C; Krajden M; Winton T; Kesten S
    Chest; 1998 Apr; 113(4):924-32. PubMed ID: 9554627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New developments in the management of cytomegalovirus infection after solid organ transplantation.
    Eid AJ; Razonable RR
    Drugs; 2010 May; 70(8):965-81. PubMed ID: 20481654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
    J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed-onset primary cytomegalovirus disease after liver transplantation.
    Arthurs SK; Eid AJ; Pedersen RA; Dierkhising RA; Kremers WK; Patel R; Razonable RR
    Liver Transpl; 2007 Dec; 13(12):1703-9. PubMed ID: 18044717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.
    Jaksch P; Zweytick B; Kerschner H; Hoda AM; Keplinger M; Lang G; Aigner C; Klepetko W
    J Heart Lung Transplant; 2009 Jul; 28(7):670-5. PubMed ID: 19560694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
    Perrottet N; Manuel O; Lamoth F; Venetz JP; Sahli R; Decosterd LA; Buclin T; Pascual M; Meylan P
    BMC Infect Dis; 2010 Jan; 10():2. PubMed ID: 20053269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.